

HDACs as regulators of T cell-mediated immunity in health and disease

SFB-F70: A special research program funded by the Austrian Science Fund (FWF).

www.meduniwien.ac.at/HIT



SFB F70 Seminar

HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cancer cell fate through the acetylated phosphatase-2A subunit PR130

Oliver Krämer, PhD

Professor of Molecular Toxicology

Department of Toxicology, University Medical Center

Thursday, 19.11. 2020, 13 Uhr

Location: Online seminar - *Webex*

<https://meduniwien.webex.com/meduniwien/j.php?MTID=md6e3d293f1b63a7801ed033b820dfde6>

Meeting number: 121 976 5511

Password: 9PmkDqMmY56 (97653766 from video systems)

Host key: 112507

Host: Christian Seiser

Biosketch

Oliver Krämer is Professor of Molecular Toxicology. He performed his PhD studies at the Georg-Speyer-Haus (GSH) in Frankfurt, and performed postdoctoral studies at the GSH and at the Friedrich-Schiller University (FSU) in Jena. After being a group leader at FSU (2010-2013), he moved to the University of Mainz as a professor of Molecular Toxicology. In his research, he is focusing on the role of posttranslational modifications (acetylation, methylation and ubiquitinylation) through genotoxins in the context of cancer.



Selected recent publications

- Beyer et al., et al., HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β -catenin, MYC, and WT1. *Cancers*. 2019, 11(10):31436.
- Göder et al., et al., HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130. *Nat Commun*. 2018, 9(1):764.
- Nikolova et al., Interstrand Crosslink Repair as a Target for HDAC Inhibition. *Trends Pharmacol Sci* 2017, 38(9):822-836.